Verastem (VSTM)
(Delayed Data from NSDQ)
$3.40 USD
-0.24 (-6.59%)
Updated Jun 7, 2024 04:00 PM ET
Pre-Market: $3.33 -0.07 (-2.06%) 8:18 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 81 - 100 ( 264 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for VSTM.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for VSTM.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Expanding Ovarian Cancer Opportunity; Higher $4.00 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
NSCLC Update at AACR; RAMP Initial Results in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 29
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
VS-6766 Ready to Enter Pivotal Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
A Strategic Shift to Focus on Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 8
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D